Date: 2013-02-06
Type of information: R&D agreement
Compound: therapeutic antibodies
Company: Antitope (UK) Eden Biodesign (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: * On February 6, 2013, Antitope has announced a research agreement with Eden Biodesign for the development of therapeutic antibodies. As part of the agreement, Antitope will apply its proprietary technologies towards the generation of a high yielding mammalian cell line for manufacture of the therapeutic.
Financial terms:
Latest news:
